Steatorrhea overview

Jump to navigation Jump to search

Steatorrhea Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Steatorrhea from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Steatorrhea overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Steatorrhea overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Steatorrhea overview

CDC on Steatorrhea overview

Steatorrhea overview in the news

Blogs on Steatorrhea overview

Directions to Hospitals Treating Steatorrhea

Risk calculators and risk factors for Steatorrhea overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Overview

Steatorrhea is the formation of non-solid feces. Stools may also float due to excess fat from malabsorption, have an oily appearance and be foul smelling. An oily anal leakage or some level of fecal incontinence may occur. There is increased fat excretion, which can be measured by determining the fecal fat level. While definitions have not been standardized, fat excretion in feces in excess of 0.3 (g/kg) / day is considered indicative of steatorrhea.

Historical Perspective

The history of celiac disease dates back to late 1800's when an english scientist described celiac disease. In October 1887, Samuel Gee, a pediatrician, was the first to describe in detail celiac disease and its association with fatty stools. In 1950, Wim Dicke's colleagues, Weijers and Van de Kamer, presented a way to diagnose mal-absorption syndromes by using stool fat measurement. In late 1960's case of idiopathic steatoeehea and reticulosis of the small bowel as a late complication was reported.

Classification

Steatorrhea may be classified based on etiology into 3 types, intestinal, biliary, and pancreatic steatorrhea.

Pathophysiology

Stearorhea can be defined as loss of undigested fat in stools. The processes can be invoked by either defect of the normal architecture of digestive tract or it may involve defect of synthesis or secretion of enzymes of GI tract which are needed to metabolize fatty content of food.

Causes

Steatorrhea may be caused by Celiac disease, choledocholithiasis, cystic fibrosis, exocrine pancreatic insufficiency, hypolipidemic drugs, inflammatory bowel disease, small bowel bacterial overgrowth syndrome.

Differentiating steatorrhea from other Diseases

Steatorrhea must be differentiated from other causes of mal-absorption such as cystic fibrosis, Hartnup'sdisease, Whipple's disease, Zollinger Ellison syndrome, acrodermatitis enteropathica, intestinal lymphangiectasia.

Epidemiology and Demographics

The demographic measures of steatorrhea can be explained by independent causes of steatorrhea.

Risk Factors

Common risk factors in the development of steatorrhea include: Celiac disease, cystic fibrosis, exocrine pancreatic insufficiency, inflammatory bowel disease, small intestinal bacterial overgrowth, hypolipidemic drugs

Screening

There is insufficient evidence to recommend routine screening for steatorrhea

Natural History, Complications, and Prognosis

If left untreated, steatorrhea can lead to severe malnutrition due to inability of gastrointestinal tract to absorb fat soluble vitamins and ultimately severe weight loss. Complication of steatorrhea include anemia, intestinal obstruction, weight loss. Prognosis of steatorrhea is generally good with appropriate treatment.

Diagnosis

Diagnostic study of choice

The 72 hr-fecal fat determination is the gold standard test for the diagnosis of steatorrhea

History and Symptoms

Mild steatorrhea can manifest as passage of frothy, foul smelling stool, greasy in appearance and difficult to flush, abdominal pain, bloating, heart burn. if severe it may cause malnutrition , dehydration,anemia, muscle weakness, weight loss, skin problems, neurological problems, osteoporosis.

Physical Examination

Patients with steatorrhea usually appear emaciated secondary to loss of subcutaneous fat. Physical examination of patients with steatorrhea is usually remarkable for distended abdomen, orthostatic hypo-tension and ecchymoses, Chvostek sign and Trousseau sign secondary to hypocalcemia.

Laboratory Findings

Quantitative analysis of fat in the stool may be helpful in the diagnosis of steatorrhea. The various tests that may be helpful in the diagnosis are acid steatocrit, near-infrared reflectance analysis (NIRA) and sudan III stain.

Imaging Findings

X-ray

There are no x-ray findings associated with steatorrhea. However, there are x-ray findings depends on the underlying causes.

CT scan

There are no CT scan findings associated with steatorrhea. However, there are CT scan findings depends on the underlying causes

MRI

There are no MRI findings associated with steatorrhea. However, there are MRI findings depends on the underlying causes.

Other Diagnostic Studies

There are no other diagnostic studies associated with steatorrhea. However, there are no other diagnostic studies depends on the underlying causes.

Treatment

Medical Therapy

Management of steatorrhea include treatment of underlying etiology, control of diarrhea and correction of nutritional deficiencies.

Surgery

Surgical intervention is usually not recommended for the management of steatorrhea. Surgery is usually reserved for patients with refractory or pre-malignant complications, such as Enteropathy Associated T-cell Lymphoma (EATL) and ulcerative jejunitis (UJ). EATL patients presenting with ulcerative lesions, stenotic lesions, and perforation needs surgical intervention. Surgery also serves as a pre-therapy in order to prevent perforation of the small bowel during chemotherapy in case of EATL. After surgery patients receive immunotherapy, chemotherapy and/or stem cell transplantation

Primary Prevention

Effective measures for the primary prevention of steatorrhea include smoking cessation, alcohol cessation, minimizing the use of certain medications, such as antibiotics, that can alter normal bowel flora, and consuming diet rich in dietary fiber.

Secondary Prevention

Secondary preventive measures of steatorrhea are similar to primary preventive measures.

References

Template:WS Template:WH